Drugs / Redasemtide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05953480 | Jul 2023 → Jun 2026 overdue | ischemic stroke | Shionogi | Active not recruiting | Missed primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-09-09 | Shionogi | Results StemRIM and Shionogi Announce Topline Results of Clinical Trials of Redasemtide in Patients with Dystrophic Epidermolysis Bullosa and Acute Ischemic Stroke shionogi.com ↗ |
| 2023-05-24 | Shionogi | Regulatory Orphan Drug Designation for Redasemtide for Dystrophic Epidermolysis Bullosa shionogi.com ↗ |
| 2021-12-13 | Shionogi | Results SHIONOGI Announces Positive Results from a Phase 2 Clinical Trial of the Regeneration Inducing Medicine S-005151 (Redasemtide) in Patients with Acute Ischemic Stroke shionogi.com ↗ |
All press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Redasemtide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05953480 ↗ |
| Known as | S-005151 | “A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke” NCT05953480 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL6068588 ↗ |
| Route | Intravenous | “Redasemtide will be administered as an intravenous (IV) infusion once daily for 5 consecutive days during hospitalization.” NCT05953480 ↗ |